Catriona John Waitt

List of Publications by Year
in descending order

44 papers	768 citations	566801 15 h-index	580395 25 g-index
44 all docs	44 docs citations	44 times ranked	949 citing authors

#	Article	IF	Citations
1	Pharmacovigilance in low‑and middle‑income countries: A review with particular focus on Africa. British Journal of Clinical Pharmacology, 2023, 89, 491-509.	1.1	31
2	Ethical issues in therapeutic use and research in pregnant and breastfeeding women. British Journal of Clinical Pharmacology, 2022, 88, 7-21.	1.1	28
3	Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clinical Pharmacokinetics, 2022, 61, 375-386.	1.6	4
4	HIV viral load non-suppression and associated factors among pregnant and postpartum women in rural northeastern South Africa: a cross-sectional survey. BMJ Open, 2022, 12, e058347.	0.8	4
5	Stable warfarin dose prediction in sub‑Saharan African patients: A machine‑learning approach and external validation of a clinical dose‑initiation algorithm. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 20-29.	1.3	10
6	Twice neglected? Neglected diseases in neglected populations. British Journal of Clinical Pharmacology, 2022, 88, 367-373.	1.1	5
7	Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‑resistant tuberculosis. British Journal of Clinical Pharmacology, 2022, 88, 3548-3558.	1.1	8
8	Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. Clinical Pharmacology and Therapeutics, 2021, 110, 36-48.	2.3	29
9	Developing and Validating a Clinical Warfarin Dose‑Initiation Model for Black‑African Patients in South Africa and Uganda. Clinical Pharmacology and Therapeutics, 2021, 109, 1564-1574.	2.3	8
10	Anticoagulation in sub‑Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. British Journal of Clinical Pharmacology, 2021, 87, 3699-3705.	1.1	12
11	Anti‑Infective Dosing in Special Populations: Pregnancy. Clinical Pharmacology and Therapeutics, 2021, 109, 977-986.	2.3	10
12	Improving anticoagulation in sub‑Saharan Africa: What are the challenges and how can we overcome them?. British Journal of Clinical Pharmacology, 2021, 87, 3056-3068.	1.1	13
13	Advancing knowledge in perinatal HIV treatment. Lancet HIV,the, 2021, 8, e124-e125.	2.1	1
14	Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. Clinical Infectious Diseases, 2021, 73, e1200-e1207.	2.9	11
15	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. Pharmaceuticals, 2021, 14, 12.	1.7	7
16	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR). Trials, 2021, 22, 831.	0.7	2
17	Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda. BMC Health Services Research, 2020, 20, 705.	0.9	10
18	Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda. BMC Public Health, 2020, 20, 1883.	1.2	9

#	Article	IF	Citations
19	Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease. Journal of Antimicrobial Chemotherapy, 2020, 75, 1772-1777.	1.3	69
20	Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. Lancet HIV,the, 2020, 7, e332-e339.	2.1	75
21	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLoS ONE, 2020, 15, e0227458.	1.1	25
22	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
23	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
24	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
25	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
26	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
27	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. , 2020, 15, e0227458.		0
28	Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?. Journal of the International AIDS Society, 2019, 22, e25372.	1.2	15
29	Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: AÂrandomised trial (DolPHIN-1 study). PLoS Medicine, 2019, 16, e1002895.	3.9	58
30	Reply to Banda et al., â€œInterpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquineâ€• Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	1
31	Transmission of CMV, HTLV-1, and HIV through breastmilk. The Lancet Child and Adolescent Health, 2019, 3, 264-273.	2.7	43
32	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. Pharmacogenomics, 2019, 20, 217-223.	0.6	4
33	Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman. Aids, 2019, 33, 2443-2444.	1.0	0
34	Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	16
35	Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African motherâ€"infant pairs. Journal of Antimicrobial Chemotherapy, 2018, 73, 1013-1019.	1.3	30
36	Validation and clinical application of a novel LCâ€"MS method for quantification of dolutegravir in breast milk. Bioanalysis, 2018, 10, 1933-1945.	0.6	3

#	Article	IF	Citations
37	Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings. Lancet HIV,the, 2018, 5, e531-e536.	2.1	52
38	High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600â€‰mg daily. Journal of Antimicrobial Chemotherapy, 2018, 73, 3158-3161.	1.3	8
39	Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LCâ€"MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1060, 300-307.	1.2	23
40	Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001â€"2010: content and utility analysis. British Journal of Clinical Pharmacology, 2016, 82, 1601-1612.	1.1	17
41	Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. Journal of Antimicrobial Chemotherapy, 2015, 70, 2816-2822.	1.3	21
42	Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. Journal of Antimicrobial Chemotherapy, 2015, 70, 1928-1941.	1.3	39
43	Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clinical Infectious Diseases, 2015, 61, 453-463.	2.9	32
44	Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. Journal of Antimicrobial Chemotherapy, 2015, 70, 555-561.	1.3	35